2 weeks Ago By ABMN Staff
NewEdge Advisors LLC grew its position in Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ) by 7.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The fund owned 24,696 shares of the medical research company’s stock after acquiring an additional 1,784 shares during the period. NewEdge Advisors LLC’s holdings in Thermo Fisher Scientific were worth $13,657,000 at the end of the most recent reporting period. A number of other institutional investors also recently modified their holdings of the company.
Beaumont Financial Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock valued at $1,278,000 after acquiring an additional 17 shares during the last quarter.
Cedar Wealth Management LLC raised its position in Thermo Fisher Scientific by 14.5% in the 1st quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock worth $78,000 after purchasing an additional 17 shares during the last quarter.
Lafayette Investments Inc. raised its position in Thermo Fisher Scientific by 2.1% in the 2nd quarter.
Lafayette Investments Inc. now owns 830 shares of the medical research company’s stock worth $459,000 after purchasing an additional 17 shares during the last quarter. Patrick M Sweeney & Associates Inc.
raised its position in Thermo Fisher Scientific by 1.8% in the 2nd quarter. Patrick M Sweeney & Associates Inc.
now owns 1,031 shares of the medical research company’s stock worth $570,000 after purchasing an additional 18 shares during the last quarter. Finally, Drive Wealth Management LLC raised its position in Thermo Fisher Scientific by 0.9% in the 2nd quarter.
Drive Wealth Management LLC now owns 2,123 shares of the medical research company’s stock worth $1,175,000 after purchasing an additional 18 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.
Analyst Upgrades and Downgrades Several research analysts recently weighed in on TMO shares. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Monday, September 16th. Raymond James increased their price target on Thermo Fisher Scientific from $650.
00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Jefferies Financial Group reissued a “buy” rating and issued a $650.
00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. JPMorgan Chase & Co.
increased their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th.
Finally, Stifel Nicolaus increased their price target on Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a research note on Friday, September 20th.
Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $650.
41. Thermo Fisher Scientific Price Performance TMO stock opened at $614.42 on Monday.
The stock has a 50-day moving average price of $606.08 and a two-hundred day moving average price of $581.88.
The stock has a market cap of $234.53 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 3.
88 and a beta of 0.78. The company has a current ratio of 1.
72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64.
Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $627.
88. Thermo Fisher Scientific ( NYSE:TMO – Get Free Report ) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.
37 EPS for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24.
Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%.
The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion.
During the same period in the prior year, the business posted $5.15 EPS. The company’s quarterly revenue was down 1.
4% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.
72 EPS for the current fiscal year. Thermo Fisher Scientific Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.
39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.
56 annualized dividend and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.
01%. Insider Activity at Thermo Fisher Scientific In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.
85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.
95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink . In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, July 26th.
The shares were sold at an average price of $600.85, for a total transaction of $180,255.00.
Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink .
Also, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.
02, for a total transaction of $2,221,584.48. Following the sale, the vice president now owns 13,699 shares of the company’s stock, valued at $8,397,760.
98. The disclosure for this sale can be found here . In the last ninety days, insiders sold 23,084 shares of company stock worth $14,094,292.
Insiders own 0.34% of the company’s stock. Thermo Fisher Scientific Profile ( Free Report ) Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.
The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. See Also Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc.
( NYSE:TMO – Free Report ). Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter .
.
